



**IMPAIRED MENINGEAL LYMPHATIC VESSEL DEVELOPMENT WORSENS STROKE OUTCOME**

**Pavel Yanev<sup>1\*</sup>, Katherine Poinatte<sup>1\*</sup>, Devon Hominick<sup>2</sup>, Noor Khurana<sup>2</sup>, Kielen R. Zuurbier<sup>1</sup>, Marcus Berndt<sup>1</sup>, Erik J. Plautz<sup>1</sup>, Michael T. Dellinger<sup>2,3†</sup>, Ann M. Stowe<sup>1†</sup>**


**Supplementary Figures**




**Supplementary Figure 1. PT-induced stroke does not affect lateral ventricle volume.** (A) Quantification of left lateral ventricle volumes in *Vegfr3*<sup>wt/wt</sup> (n=5; blue triangles) and *Vegfr3*<sup>wt/mut</sup> (n=5; red triangles) mice without injury was analyzed using a Mann-Whitney test (p=0.25). (B) Lateral ventricle volumes for *Vegfr3*<sup>wt/wt</sup> (n=10; blue squares) and *Vegfr3*<sup>wt/mut</sup> (n=10; red squares) mice analyzed by two-way ANOVA. Values shown are mean ± SD.



**Supplementary Figure 2. No effect of lymphatic hypoplasia on motor recovery after stroke.** (A) Strain differences in acquisition of the Rotarod task during training were analyzed using a 2-way repeated measures ANOVA ( $F_{(10,360)}=1.23$ ;  $p=0.27$ ). Multiple comparisons between *Vegfr3*<sup>wt/wt</sup> (blue, solid line) and *Vegfr3*<sup>wt/mut</sup> (red, dashed lines) mice were performed for each day of training. (B) A repeated measures 2-way ANOVA was performed ( $F_{(3,54)}=0.91$ ;  $p=0.44$ ) in which multiple comparisons between strain were performed at day 2 ( $p=0.74$ ), day 7 ( $p=0.34$ ), and day 14 ( $p=0.09$ ) and multiple comparisons were performed between baseline and day 2, 7, and 14 for each strain following PT ( $n=10$ /group). (C) Motor recovery after tMCAo (days post-stroke, x axis) was analyzed with a repeated measures 2-way ANOVA was performed ( $F_{(3,48)}=1.21$ ;  $p=0.32$ ) in which multiple comparisons between strain were performed at day 2 ( $p=0.78$ ), day 7 ( $p=0.27$ ), and day 14 ( $p=0.16$ ) and multiple comparisons were performed between baseline and day 2, 7, and 14 for *Vegfr3*<sup>wt/wt</sup> ( $n=8$ ) and *Vegfr3*<sup>wt/mut</sup> ( $n=6$ ) strains. Neurological deficit scores for (D) PT cohorts and (E) tMCAo cohorts show no effect of genotype ( $p=0.72$  and  $p=0.30$ , respectively). \*\* $p<0.01$ , \*\*\* $p<0.001$ , \*\*\*\* $p<0.0001$  vs. baseline pre-stroke values.



**Supplementary Figure 3. Ventricle volumes after tMCAo.** Lateral ventricle volumes for *Vegfr3*<sup>wt/wt</sup> (blue circles; n=8) and *Vegfr3*<sup>wt/mut</sup> (red circles; n=6) mice of mice analyzed by two-way ANOVA show no effect by genotype. Values are mean ± SD.



**Supplemental Figure 4. PT, but not tMCAo, induces meningeal angiogenesis.** Representative images of meninges stained with an anti-CD31 antibody. Meninges were collected and stained from animals two-weeks after PT or tMCAo. (A,B) PT mice (n = 6) had more meningeal blood vessels than sham mice (n = 5). (C,D) The density of meningeal blood vessels was not different between sham (n = 5) and tMCAo (n = 4) mice.